Position in ERAS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7,740,987
+$904,242 QoQ
Shares Held
422,543
0.0% QoQ
Ownership
0.121%
of shares outstanding
% of Portfolio
1.52%
of 13F equity value
Holder Rank
#66
of 257 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ERAS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Spruce Street Capital LP holds $397,390,268 across 24 Biotechnology names. ERAS ranks #17 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RLAY |
Relay Therapeutics, Inc.
|
2,984,125 | $55,832,978 | |
| 2 | LBRX |
Lb Pharmaceuticals Inc
|
1,376,159 | $44,663,240 | |
| 3 | RLMD |
Relmada Therapeutics, Inc.
|
6,391,328 | $44,227,989 | |
| 4 | ANRO |
Alto Neuroscience, Inc.
|
1,353,047 | $35,706,910 | |
| 5 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
354,816 | $34,587,463 | |
| 6 | SVRA |
Savara Inc
|
3,452,576 | $21,267,868 | |
| 7 | PCVX |
Vaxcyte, Inc.
|
306,047 | $17,790,512 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
|
329,006 | $16,697,054 |
All Filings in ERAS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,740,987 | 422,543 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $6,836,745 | 422,543 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $14,469,431 | 3,889,632 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||